Clinical trial · no report yet · Phase 1/Phase 2
NCT05265091
A Study of KL590586 in Patients With Advanced Solid Tumors
- NCT05265091 ↗
- Active not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
- Phase
- Phase 1/Phase 2
- Status
- Active not recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- KL590586 Capsule
- Arms
- KL590586 · Experimental
- Enrollment
- 414 (estimated)
- Primary outcomes
- Phase I: Dose limiting toxicities (DLT)
- Phase II: ORR
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Sep 15, 2021
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05265091 · updated May 8, 2026